Press release
Tyrosine Kinase Market Increasing Demand, Growth Analysis and Future Outlook by 2031
The global tyrosine kinase market is anticipated to witness a considerable CAGR of during the forecast period. The rising prevalence of cancer across the globe along with the growing R&D of new tyrosine kinase inhibitors is a key factor anticipated to drive the growth of the global tyrosine kinase market. According to the World Health Organization (WHO), cancer is the second leading cause of mortality across the globe which is responsible for around 9.6 million mortalities and accounted for 18.1 million new cases in 2018, globally. 1 in 5 men and 1 in 6 women, across the globe, develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease.A full report of Tyrosine Kinase Market is available at: https://www.omrglobal.com/industry-reports/tyrosine-kinase-market
The tyrosine kinase inhibitors are given to the patients in order to stop the growth of cancer cells. Therefore, the high prevalence of different kinds of cancers is anticipated to create the demand for these drugs, which in turn is driving the growth of the tyrosine kinase inhibitor drugs across the globe.
GlaxoSmithKline PLC, Novartis International AG, Pfizer Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eisai Co., Ltd., Eurofarma Laboratórios S/A, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, and so on are the key companies operating in the tyrosine kinase market across the globe. The major players of the tyrosine kinase market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are driving the growth of the global tyrosine kinase market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/tyrosine-kinase-market
Recent Development in the Market
In May 2018, Pfizer, Inc. had announced the US Food and Drug Administration (FDA) approval for the breakthrough therapy designation for XALKORI (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. In addition, the FDA had granted breakthrough therapy designation for XALKORI for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.
Global Tyrosine Kinase Market Segmentation
By Type
• BCR-ABL Tyrosine Kinase Inhibitor
• Epidermal Growth Factor Receptor (EGFR)
• Vascular Endothelial Growth Factor Receptor (VEGFR)
• Anaplastic Lymphoma Kinase (ALK)
• Others
By Application
• Chronic Myeloid Leukemia (CML)
• Lung Cancer
• Breast Cancer
• Renal Cell Cancer
• Other
Tyrosine Kinase Market- Segment by Region
North America
• United States
• Canada
Europe
• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World
• Middle East & Africa
• Latin America
Company Profiles
• ARIAD Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Eisai Co., Ltd.
• Eurofarma Laboratórios S/A
• Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson and Johnson
• Merck & Co., Inc.
Reasons to Buying From us -
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
Visit more report at
https://www.linkedin.com/pulse/scaffold-technology-market-size-trends-latest-arti-vishwakarma-mlsof/
https://www.linkedin.com/pulse/aesthetic-threads-market-increasing-demand-growth-2031-vishwakarma-pyg5f
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tyrosine Kinase Market Increasing Demand, Growth Analysis and Future Outlook by 2031 here
News-ID: 3454211 • Views: …
More Releases from Orion Market Research

Infrastructure as Code (IaC) Service Market Size Analysis, Competitive Insights, …
Infrastructure as Code (IaC) Service Market was valued at approximately USD 0.932 billion, and it's projected to expand to around USD 7.509 billion by 2033, achieving a robust CAGR of 23.2% from 2024 to 2033.
Infrastructure as Code (IaC) Service Market Overview
The Infrastructure as Code (IaC) Service Market is experiencing remarkable expansion, fueled by the escalating need for scalable, automated infrastructure deployment across cloud and enterprise environments. In 2023, the market…

Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market : A Guide to …
Ultra High‐Performance Liquid Chromatography (UHPLC) Columns Market is estimated to be valued at USD 2.5 billion, and is projected to grow to approximately USD 4.8 billion by 2033, representing a compound annual growth rate (CAGR) of about 7.8% from 2024 to 2033.
Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market Overview
The UHPLC columns market is on a strong growth trajectory, fueled by increasing demand for rapid, high-resolution analytical techniques across pharmaceuticals, biotechnology,…

Property Management Service Market Rising Demand and Growth Forecast Through 203 …
Property Management Service Market was valued at approximately USD 17.3 billion. It is anticipated to reach around USD 32.0 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2033.
Property Management Service Market Overview
The Property Management Service Market is witnessing steady growth due to increasing urbanization, rising investments in real estate, and a growing demand for outsourced property management solutions. Property owners are increasingly…

5G Chipset Market Set to Witness Significant Growth by 2033 | Apple Inc., HiSili …
The global 5G chipset market was valued at USD 33.75 billion in 2024 and is projected to reach USD 502.66 billion by 2033, growing at a compound annual growth rate (CAGR) of 35% from 2025 to 2033.
5G Chipset Market Overview
The 5G chipset market is experiencing rapid growth, driven by the global rollout of 5G networks and the increasing demand for high-speed, low-latency connectivity across various applications, including smartphones, IoT…
More Releases for Kinase
Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipelin …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors
2. Tyrosine Kinase: An Overview
3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies
4. Types of Tyrosine Kinase Receptors
4.1 Epidermal Growth Factor Receptor
4.1.1 Types of Epidermal Growth Factor Receptor
4.1.2 Epidermal Growth Factor Receptor & Ligands
4.1.3…
Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Bet …
According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.
Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157712
Mitogen Activated Protein Kinase Kinase Kinase 7…
Tyrosine Protein Kinase JAK3 (Janus Kinase 2 or JAK3 or EC 2.7.10.2) – Pharmac …
Market Research Hub report titled ‘Tyrosine Protein Kinase JAK3 Pipeline’ (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a…
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline …
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with…
Orbis Research - Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Cataly …
Description:
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 9…
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stres …
Market Reports Centers, Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016, provides in depth analysis on Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c…